Last reviewed · How we verify
Neckshoulderarm syndrome — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Voltaren | DICLOFENAC | Hisamitsu Pharmaceutical Co., Inc | Nonsteroidal Anti-inflammatory Drug | Prostaglandin G/H synthase 2 | 1988-01-01 | |
| Arthrotec | Diclofenac Sodium | Pfizer | diclofenac | Acid-sensing ion channel 3 | 1988-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Hisamitsu Pharmaceutical Co., Inc · 1 drug in Neckshoulderarm syndrome
- Pfizer · 1 drug in Neckshoulderarm syndrome
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Neckshoulderarm syndrome:
- Neckshoulderarm syndrome treatment updates — RSS
- Neckshoulderarm syndrome treatment updates — Atom
- Neckshoulderarm syndrome treatment updates — JSON
Cite this brief
Drug Landscape (2026). Neckshoulderarm syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neckshoulderarm-syndrome. Accessed 2026-06-10.
Related
- Neckshoulderarm syndrome full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing